



Advances in Cardiovascular Regenerative Medicine

00: 20. A
S PSC
21.
A
R M U P M G I
R M H S C I M
S T F D H O F
I S C B R M
S S M 22 A S C I
D R M C U D

K (ESC)-
 (LAD) ESC-
 43. R-294
 MSC (E MSC). RNA
 E MSC- R-21,
 E MSC 44. I
 R-210
 45.
 I J MSC ER (J-MSC-ER)
 ER 46. F MSC-ER
 RNA-181
 TNF IL-6
 IL-10 47. MSC
 48.
 49-50.

U (ESC), PSC
 59. C MI
 (PSC-CM) MSC- (MSC-
 PA) 60. B MSC-PA
 PSC-CM N
 PSC-CM CM-
 MSC-PA
 A MI 60. (2020) CRISPR/
 C 9 MHC I 2
 (B2M), PSC- MSC (PSC-
 T 0.233T 0.1)T -0.066 .07 (U R4)T -0.

Anti-inflammatory effects of MSCs in cardiac tissue

I MSC
 48-51. C MSC
 52.
 M2, E2-
 CD8⁽⁺⁾ T
 T (T_H) 52. A
 CD206
 MSC 53.
 CD206, IL-10
 F
 MSC
 IL12 TNF-
 IL6, 53. I
 MSC
 N (NO).N NO. T-
 T- MSC
 NO. T-
 54-56. F MSC NOS/
 NOS3
 MI 57, NOS
 MSC 58.

iPSC therapy for cardiac regeneration

P PSC

...
A ...
... FDA ...
... D ...
...
FDA ... N ...
... 1,200 ...
... (...) . A ... 2021 ... 383 ... 1,
685 ... 2 ... 152 ... 3 ... G ...
... 50% ... O ... D ...
... I ... O ... 8% ...
... 2025.

COVID-19 and Long-COVID (AKA Long Hauler

79 , 80-81 , 82 ,
83 ,
0
0
84
0 0 0 80% - 0

IEËËY ~ ÆÜËËY æ) * ÆRËËVæ) ÆY ÆY ËËRæ) * ÆYËËY æ) * ÆÜËË^clæ]ËËGËGËD\ËËØççæ&^|| ~ |æ;ËÇ^•æ&|^• Æ
-i [{ Æ @ ~ { æ) Æ ^ { ai ~ [] } Æ& Æ •c^ { Æ &^||ËË^Ëç^äË &æ;äË [çæ• & ~ |æ;ËË] ; [^•^ } æ [Æ Æ &^|| Æ
promote cardiac infarct healing through reducing cardiomyocyte death and
promoting angiogenesis. ÆÖ^|| ÆÖ^æ@ ÆÖ; ÆFFËËFËFËË ËË
IFËËÖ [^ ÆŠTËËY æ) * Æ T Z ÆÇGËFJ D Æ U çç^ çç^ , Æ [- Æ Ø ççæ & ^ || ~ |æ;Ë X ^ • æ & | ^ • Ë Æ V @ Æ Æ Æ Æ U Æ Æ * ä) Ë Æ